Zimmer Biomet Holdings, Inc.(ZBH)

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest News & Analysis
ZBH Credibility Inflection: ROSA OptimiZe Clearance Validates Robotics Innovation Pipeline
FDA clears enhanced ROSA robotic platform weeks ahead of schedule, restoring investor confidence in ZBH's innovation roadmap after November earnings miss.
Zimmer Biomet's Execution Reality Check: Q3 Earnings Miss Undermines Ecosystem Narrative
ZBH Q3 miss and guidance cut trigger investor litigation. Robotics adoption, international weakness, and M&A execution now under scrutiny.
Zimmer Biomet's Q3 Momentum: Robotics Ecosystem Aligns with Earnings Catalyst
ZBH Q3 earnings on Nov. 5 expected to validate robotics adoption and M&A integration. Consensus guides 10.2% revenue growth.
Zimmer Biomet Q4 2024 Earnings Analysis: Growth vs. Margin Pressures
Zimmer Biomet’s Q4 2024 earnings beat estimates with solid revenue growth but concerns over margin contraction, a strong dollar, and short‐term EPS dilution raise questions for 2025.
Zimmer Biomet (ZBH): Navigating Growth in the Medical Device Market
Zimmer Biomet (ZBH) balances Q4 earnings with 2025 profit concerns. Strategic initiatives aim to drive growth, but currency headwinds and margin pressures persist.
Zimmer Biomet (ZBH) Q4 Earnings Analysis: Navigating Headwinds
Zimmer Biomet's Q4 earnings beat estimates, but currency headwinds and margin compression loom. A deep dive into ZBH's strategic moves and market outlook.
Zimmer Biomet (ZBH): Q4 Earnings, Strategic Initiatives, and Market Outlook
Zimmer Biomet (ZBH) navigates Q4 earnings, strategic shifts, and market headwinds. Paragon 28 acquisition and GLP-1 impacts analyzed. Actionable insights provided.
Zimmer Biomet (ZBH): Earnings, Acquisitions, and Market Outlook
Zimmer Biomet (ZBH) faces margin contraction despite earnings beat. Explore the Paragon 28 acquisition, marketing strategies, and leadership changes impacting this medical device leader.
Zimmer Biomet (ZBH): FDA Clearance, Acquisition & Market Outlook
Zimmer Biomet (ZBH) navigates FDA clearance, strategic acquisitions, and macroeconomic headwinds. A deep dive into ZBH's market positioning and future prospects.
Zimmer Biomet (ZBH): Acquisitions, Innovation, and Growth
Zimmer Biomet (ZBH) is strategically expanding through acquisitions and innovation. This analysis covers recent developments and their impact on the company's financial outlook.
Zimmer Biomet (ZBH): Innovations, Acquisitions, and Growth
Zimmer Biomet navigates market dynamics with strategic acquisitions, innovations like the Persona Revision SoluTion Femur, and global expansion amid currency headwinds.
Zimmer Biomet (ZBH): Navigating Innovation, Acquisitions, and Market Shifts
Zimmer Biomet (ZBH) navigates the orthopedic market with strategic acquisitions, innovation, and global expansion, facing currency and GLP-1 drug challenges.
Zimmer Biomet (ZBH): Acquisitions, Innovation, and Market Dynamics
Zimmer Biomet navigates growth through strategic acquisitions, product innovation, and market expansion amid rising costs and FX headwinds. Investors should monitor financial performance and strategic initiatives.
Zimmer Biomet (ZBH): Strategic Shifts & Financial Analysis
Zimmer Biomet navigates a complex market with strategic leadership changes and acquisitions, impacting its financial trajectory.
Zimmer Biomet Holdings 2025 Update: Navigating Acquisition Impact and Macroeconomic Challenges
Zimmer Biomet's 2025 growth is shaped by the Paragon 28 acquisition and macroeconomic pressures, affecting EPS guidance and strategic positioning.
Zimmer Biomet Holdings Inc. (ZBH) Strategic Leap with Monogram Acquisition and Financial Insights
Zimmer Biomet's acquisition of Monogram Technologies marks a strategic advance in autonomous orthopedic robotics, supported by solid financial performance and growth prospects.
Zimmer Biomet Holdings Inc. Strategic Robotics Acquisition & Financial Analysis - Monexa AI
Zimmer Biomet's $177M Monogram acquisition advances orthopedic robotics; financials reveal growth, cautious investor sentiment, and competitive dynamics in surgical tech.
Zimmer Biomet Holdings Inc. Advances Autonomous Surgical Robotics with $177M Monogram Acquisition
Zimmer Biomet accelerates its autonomous robotics strategy with $177M Monogram deal, challenging Stryker's Mako dominance and reshaping orthopedic surgery dynamics.
Zimmer Biomet Holdings Inc. Strategic Acquisition and Financial Analysis - Market Impact & Robotics Leadership
Zimmer Biomet's acquisition of Monogram Technologies marks a pivotal step in autonomous orthopedic robotics, challenging Stryker Mako and impacting financial outlook.
Zimmer Biomet Holdings (ZBH) Q2 2025 Update: Robotics Acquisition Drives Autonomous Surgery Growth
Zimmer Biomet advances in orthopedic robotics with Monogram acquisition, impacting Q2 earnings and positioning ZBH against competitors like Stryker.
Zimmer Biomet Holdings Q2 2025 Beat and Raise: Orthopedic Demand Drives Growth
Zimmer Biomet (ZBH) surpasses Q2 earnings expectations with 7% revenue growth, driven by strong orthopedic demand and strategic acquisitions, raising full-year guidance.
Zimmer Biomet (ZBH): Q2 Beat, Monogram Buy and the Road to Robotic Autonomy
Zimmer Biomet’s Q2 beat and $177M Monogram acquisition accelerate a robotics-led growth vector; cash flow strength funds rollout but execution and adoption risk remain.
Zimmer Biomet (ZBH): Profitability Slips, Cash Flow and Buybacks Keep Balance Sheet Intact
Zimmer Biomet reported FY2024 revenue of **$7.68B** (+3.93% YoY) while net income fell to **$903.8MM** (-11.62%); free cash flow stayed strong at **$1.14B**.